|
 |
amlodipine besylateThis page contains recent news articles, when available, and an overview of amlodipine besylate but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: amlodipine besylate (when available) Zolmitriptan is a selective 5-hydroxytryptamine receptor subtype agonist indicated for the acute treatment of migraine attacks with or without aura in adults. Zolmitriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Zolmitriptan is an agonist for a vascular 5-hydroxytryptamine receptor subtype (probably a member of the 5-HT1D family) having only a weak affinity for 5-HT1A, 5-HT5A, and 5-HT7 receptors and no significant affinity or pharmacological activity at 5-HT2, 5-HT3 or 5-HT4 receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Zolmitriptan also activates 5-HT1 receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Zolmitriptan in humans. For the acute treatment of adult migraine (with or without auras) Mechanism Of Action: Zolmitriptan binds with high affinity to human 5-HT1B and 5-HT1D receptors leading to cranial blood vessel constriction. Current theories proposed to explain the etiology of migraine headache suggest that symptoms are due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of zolmitriptan for the treatment of migraine headache can most likely be attributed to the agonist effects at the 5HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release. News Articles on Zolmitriptan Ranbaxy to launch anti-hypertensive drug in Africa - Dec 21, 2009 ...as Olvance in India in April 2009, followed by the August launch of Ol-Vamlo, a fixed-dose combination of Olmesartan Medoxomil with Amlodipine Besylate. Economic Times Part D Negotiation Will Save Medicare And Seniors Billions - Oct 30, 2009 For example: - Part D plans spend 99.7% more than the VA for the generic form of the hypertension drug Norvasc (amlodipine besylate). ... Medical News Today (press release) Canadian Patent Disclosure Requirements Clarified - Oct 20, 2009 As amlodipine and its pharmaceutically acceptable salts had been claimed previously, the Court considered whether the claim to amlodipine besylate qualified ... Mondaq News Alerts (registration) GreenMeds Store - norvasc - Oct 31, 2009 Differential roles of ingredient, amlodipine besylate is 10 milligrams once a day anyway! It is important are feeling well. If used for angina a feeling ... Newstalk ZB Court Report - Oct 25, 2009 ...in Lipitor® -- and amlodipine besylate -- the active ingredient in Norvasc® -- used to treat high cholesterol in combination with treating hypertension, ... Patent Docs (blog) Brand Names/Synonyms: amlodipine besylate is also known by the following brand names and/or synonyms311C90; Zolmitriptan; Zomig; Zomig-Zmt Drug Category: amlodipine besylate is categorized under the following by the FDA: Anti-migraine Agents; Vasoconstrictor Agents; Anti-inflammatory Agents; Selective Serotonin Agonists; ATC:N02CC03 Dosage Forms: SPRAY; TABLET Absorption: 40% Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
